Physician profile
Meng Wu
NPI 1548721996
$790.07
in general payments reported to CMS, 2019-2025
12 companies · $394 in 2025
The $394 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2024: $271 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $665.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $146.48 | 2024 | |
| Intuitive Surgical, INC. | $128.75 | 2025 | |
| Amgen INC. | $125.00 | 2022 | |
| Pfizer INC. | $125.00 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $115.11 | 2025 | Lynparza, Tagrisso |
| Bayer Healthcare Pharmaceuticals INC. | $28.14 | 2025 | |
| Novartis Pharmaceuticals Corporation | $23.99 | 2025 | |
| Beone Medicines USA, INC. | $23.05 | 2025 | Brukinsa |
| Incyte Corporation | $19.56 | 2025 | Jakafi |
| Emd Serono, INC. | $18.97 | 2025 | |
| Genentech USA, INC. | $18.10 | 2025 | Columvi |
| Daiichi Sankyo INC. | $17.92 | 2025 | Datroway |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meng Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.